• Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL

  NCT02656147

  Unknown statusInterventionalPhase 1Updated Sep 5, 2017
• Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

  NCT03271515

  Unknown statusInterventionalPhase 1Updated Jan 20, 2021
• Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia

  NCT04100187

  Unknown statusInterventionalPhase 1Updated Dec 1, 2022
• Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL

  NCT04163575

  Unknown statusInterventionalPhase 1Phase 2Updated Dec 23, 2019
• T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

  NCT02772198

  Unknown statusInterventionalPhase 1Phase 2Updated Nov 3, 2020
• Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

  NCT06364423

  RecruitingInterventionalPhase 1Phase 2Updated Jul 16, 2026

ClinicalTrials.gov ID

NCT02546739

Lead Sponsor

Beijing Doing Biomedical Co., Ltd.INDUSTRY

Overall Status

Unknown status

Study Type

Interventional

Phase

Phase 1

Enrollment

100Estimated

Last Update Posted

Jan 26, 2021Actual

Start Date

Mar 1, 2021Estimated

Primary Completion Date

Mar 1, 2022Estimated

Completion Date

Mar 1, 2023Estimated

Official Title

Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies

Brief Summary

This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ haematological malignancies.

Detailed Description

This is a multi-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product named CD19 Chimeric Antigen Receptor (CAR) T-cells (CD19 CAR T-cells) in patients with high risk, relapsed CD19+ haematological malignancies (Leukemia and lymphoma). Following informed consent and registration to the trial, patients will undergo an unstimulated leukapheresis for the generation of the CD19 CAR T-cells. Patients will receive the CD19CAR T-cells following lymphodepleting chemotherapy. The study will evaluate the safety, efficacy and duration of response of the CD19 CAR T-cells in patients with high risk relapsed CD19+ malignancies.

• Leukemia
• Lymphoma

• Anti-CD19-CAR

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Relapsed or refractory B cell derived acute lymphoblastic leukemia(ALL), chronic lymphoblastic leukemia(CLL) and non-hodgkin lymphoma.
2. KPS>60.
3. Life expectancy>3 months.
4. Gender unlimited, age from 18 years to 70 years.
5. CD19 expression must be detected on greater than 15% of the malignant cells by immunohistochemistry or greater than 30% by flow cytometry.
6. Patients who have failed at least one line of a standard treatment.
7. No serious mental disorder.
8. Patients must have adequate cardiac function(no cardiac disease, LVEF≥40% ), adequate pulmonary function as indicated by room air oxygen saturation of >94%, and adequate renal function(Cr≤133umol/L).
9. No other serious diseases(autoimmune disease, immunodeficiency etc.).
10. No other tumors.
11. Patients volunteer to participate in the research.
12. Patients with history of allogeneic stem cell transplantation are eligible if at least 100 days post-transplant, if there is no evidence of active GVHD and no longer taking immunosuppressive agents for at least 30 days prior to trial.

Exclusion Criteria:

1. KPS<50.
2. Patients are allergic to cytokines.
3. Central nervous system leukemia within 28 days.
4. Uncontrolled active infection.
5. Acute or chronic GVHD.
6. Treated with T cell inhibitor.
7. Pregnancy and nursing females.
8. HIV/HBV/HCV Infection.
9. Other situations we think improper for the research.

Primary Purpose

Treatment

Allocation

Non-Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Beijing Doing Biomedical Co., Ltd.INDUSTRY

Collaborators

The First Hospital of Jilin UniversityOTHER

Hebei Yanda Ludaopei HospitalOTHER

086-13269099630